Personal information

No personal information available

Activities

Works (5)

Tocilizumab for Steroid Pulse-Refractory Cytokine Release Syndrome in Chemotherapy With Durvalumab Plus Tremelimumab for Non-Small Cell Lung Cancer: A Case Report

JTO Clinical and Research Reports
2025-01 | Journal article
Contributors: Ken Yamamoto; Katsuya Hirano; Temiko Shimada; Akito Hata
Source: check_circle
Crossref

Afatinib plus bevacizumab combination after osimertinib resistance in advanced EGFR-mutant non-small cell lung cancer: Phase II ABCD-study

Lung Cancer
2024-11 | Journal article
Contributors: Akito Hata; Nobuyuki Katakami; Naoto Takase; Kayoko Kibata; Yuta Yamanaka; Motohiro Tamiya; Masahide Mori; Takashi Kijima; Satoshi Morita; Kazuko Sakai et al.
Source: check_circle
Crossref

A DPC Database Study on the Safety of Atezolizumab/Bevacizumab/Carboplatin/Paclitaxel in Non-small Cell Lung Cancer in Japanese Patients

Advances in Therapy
2024-09 | Journal article
Contributors: Akito Hata; Shunichiro Iwasawa; Yusuke Sasaki; Kosei Tajima; Yasutaka Chiba
Source: check_circle
Crossref

Treatment preferences among Japanese patients and physicians for epidermal growth factor receptor‐mutant non‐small cell lung cancer

Cancer Medicine
2024-01 | Journal article
Contributors: Akito Hata; Simon Fifer; Kazuo Hasegawa; Emiko Ando; Mami Kasahara‐Kiritani; Michiko Takahashi; Robyn Ordman; Lili Toh; Akira Inoue
Source: check_circle
Crossref

Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE

Journal of Clinical Oncology
2022-01-10 | Journal article
Contributors: Akito Hata; Isamu Okamoto; Naoki Inui; Morihito Okada; Masahiro Morise; Kohei Akiyoshi; Masayuki Takeda; Yasutaka Watanabe; Shunichi Sugawara; Naofumi Shinagawa et al.
Source: check_circle
Crossref

Peer review (3 reviews for 2 publications/grants)

Review activity for Advances in therapy. (1)
Review activity for JTO clinical and research reports. (2)